Finance

Lists
BM8:FRA
Biomarin Pharmaceutical Inc
€56.38
0.00%
(0.00) 1D
Sep 11, 8:01:43 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BM8...
Mkt. cap
12.71B
Avg. vol.
198.00
Volume
0.00
52-wk high
€60.74
52-wk low
€42.62
No. of employees
3K
Mkt. cap
12.71B
Avg. vol.
198.00
Volume
0.00
52-wk high
€60.74
52-wk low
€42.62
No. of employees
3K
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
776.13M
874.56M
766.21M
989.71M
Cost of goods sold
549.56M
348.91M
373.80M
398.05M
Cost of revenue
549.56M
348.91M
373.80M
398.05M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
268.42M
324.16M
249.98M
308.73M
Operating expense
273.26M
329.01M
254.46M
382.22M
Total operating expenses
822.82M
677.92M
628.26M
780.27M
Operating income
-46.69M
196.64M
137.95M
209.44M
Other non operating income
5.09M
1.02M
3.96M
3.28M
EBT including unusual items
-26.32M
-27.15M
141.20M
61.38M
EBT excluding unusual items
-26.32M
214.10M
149.52M
159.91M
Income tax expense
4.42M
19.42M
35.68M
16.62M
Effective tax rate
-16.79%
-71.52%
25.27%
27.08%
Other operating expenses
-
-
-
-
Net income
-30.74M
-46.57M
105.53M
44.76M
Net profit margin
-3.96%
-5.33%
13.77%
4.52%
Earnings per share
0.12
0.46
0.76
1.20
Interest and investment income
17.85M
19.21M
22.56M
10.48M
Interest expense
-2.58M
-2.78M
-14.96M
-63.30M
Net interest expenses
15.28M
16.43M
7.60M
-52.82M
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.20M
209.68M
154.36M
307.08M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps